NAYA Biosciences Files S-1/A Amendment
Ticker: IVF · Form: S-1/A · Filed: Jan 7, 2025 · CIK: 1417926
Sentiment: neutral
Topics: sec-filing, registration, amendment
TL;DR
NAYA Bio (formerly INVO) filed an S-1/A. Looks like they're still prepping for something big.
AI Summary
NAYA Biosciences, Inc. filed an S-1/A amendment on January 7, 2025, for its registration statement. The company, formerly known as INVO Bioscience, Inc., is incorporated in Nevada and operates in the surgical and medical instruments sector. Its principal executive offices are located at 5582 Broadcast Court, Sarasota, Florida.
Why It Matters
This filing indicates NAYA Biosciences is actively pursuing its registration process, which could lead to new equity offerings or significant corporate changes impacting investors.
Risk Assessment
Risk Level: medium — S-1/A filings often precede significant corporate actions like stock offerings, which can introduce volatility and dilution risk.
Key Numbers
- 333-283872 — SEC File Number (Identifies the specific registration filing with the SEC.)
- 3841 — SIC Code (Indicates the company operates in the Surgical & Medical Instruments & Apparatus industry.)
Key Players & Entities
- NAYA Biosciences, Inc. (company) — Registrant
- January 7, 2025 (date) — Filing date
- INVO Bioscience, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- 5582 Broadcast Court Sarasota, Florida, 34240 (address) — Principal executive offices
- Steve Shum (person) — Chief Executive Officer
- Daniel Teper (person) — President
FAQ
What is the primary purpose of this S-1/A filing?
This S-1/A filing is an amendment to NAYA Biosciences, Inc.'s Form S-1 Registration Statement, indicating updates or revisions to their initial filing.
When was this amendment filed with the SEC?
The amendment was filed as of January 7, 2025.
What was NAYA Biosciences, Inc. previously known as?
NAYA Biosciences, Inc. was formerly known as INVO Bioscience, Inc.
Where are NAYA Biosciences, Inc.'s principal executive offices located?
Their principal executive offices are located at 5582 Broadcast Court, Sarasota, Florida, 34240.
What industry does NAYA Biosciences, Inc. operate in?
NAYA Biosciences, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, as indicated by its SIC Code 3841.
Filing Stats: 4,370 words · 17 min read · ~15 pages · Grade level 15.6 · Accepted 2025-01-07 08:18:15
Key Financial Figures
- $13,000,000 — , 2025 NAYA Biosciences, Inc. Up to $13,000,000 of Units, each consisting of One Shar
- $0.0001 — of one share of common stock, par value $0.0001 per share (the “Common Stock&rdqu
- $0.87 — at an assumed public offering price of $0.87 per Unit. The warrants are exercisable
- $0 — includes a share of Common Stock, minus $0.0001, and the exercise price of the Pre
Filing Documents
- forms-1a.htm (S-1/A) — 1972KB
- ex1-1.htm (EX-1.1) — 136KB
- ex4-1.htm (EX-4.1) — 39KB
- ex4-27.htm (EX-4.27) — 125KB
- ex4-28.htm (EX-4.28) — 121KB
- ex5-1.htm (EX-5.1) — 26KB
- ex10-73.htm (EX-10.73) — 256KB
- ex23-1.htm (EX-23.1) — 7KB
- ex24-1.htm (EX-24.1) — 28KB
- ex107.htm (EX-FILING FEES) — 21KB
- forms1_001.jpg (GRAPHIC) — 26KB
- forms1_002.jpg (GRAPHIC) — 32KB
- forms1_003.jpg (GRAPHIC) — 205KB
- forms1_004.jpg (GRAPHIC) — 13KB
- forms1_005.jpg (GRAPHIC) — 163KB
- forms1_006.jpg (GRAPHIC) — 306KB
- forms1_007.jpg (GRAPHIC) — 200KB
- ex23-1_001.jpg (GRAPHIC) — 11KB
- ex5-1_001.jpg (GRAPHIC) — 9KB
- 0001493152-25-001123.txt ( ) — 4064KB
BUSINESS
BUSINESS DESCRIPTION 68 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 81
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 103
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 111 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE 112
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 113 PLAN OF DISTRIBUTION 118 LEGAL MATTERS 125 EXPERTS 125 WHERE YOU CAN FIND MORE INFORMATION 125 INCORPORATION OF DOCUMENTS BY REFERENCE 126 PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference into this prospectus. This summary does not contain all of the information that you should consider before investing in our Common Stock. You should carefully read this entire prospectus, and our other filings with the SEC, including the following sections, which are either included herein and/or incorporated by reference herein, “Risk Factors”, “Special Note Regarding Forward-Looking Statements”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements incorporated by reference herein, before making a decision about whether to invest in our securities . In this prospectus, unless context requires otherwise, references to “we,” “us,” “our,” “NAYA” or “the Company” refer to NAYA Biosciences, Inc. and its subsidiaries. THE COMPANY NAYA Biosciences is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility. The Company utilizes a hub and spoke model that harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets as well as optimized return on investment by combining the upside of innovative clinical-stage therapeutics with scalable, profitable commercial revenues. The hub-and-spoke structure uses a centralized portfolio management team (the parent company or “Hub”) that owns and controls a set of subsidiaries (“Spokes”). The subsidiaries remain focused on their as